1
|
Jalalzadeh M, Mousavinasab S, Villavicencio C, Aameish M, Chaudhari S, Baumstein D. Consequences of Interdialytic Weight Gain Among Hemodialysis Patients. Cureus 2021; 13:e15013. [PMID: 34136313 PMCID: PMC8197628 DOI: 10.7759/cureus.15013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/13/2021] [Indexed: 11/05/2022] Open
Abstract
Background Interdialytic weight gain (IDWG) is a marker of higher pre-dialysis blood pressure, nutrition, and survival in hemodialysis (HD) patients. However, this relationship is incompletely characterized. In this study, we seek to define the association of IDWG/dry weight x100 (IDWG%) on blood pressure (BP), and the nutritional status of an HD population. Material and Methods This study was performed on 300 HD patients. The data was collected over four weeks, including total IDWG, IDWG%, and blood pressure. Normalized protein nitrogen appearance (nPNA), and serum albumin were used as markers of nutritional status. Participants were divided into three groups according to the mean of the IDWG% between two sessions of HD (group A < 3%, group B = 3% - 3.9%, and group C ≥ 4%); they were then compared on various aspects. Student t-test, analysis of variance (ANOVA), and linear regression analysis were used as statistical tools. Results The mean (± standard deviation (SD)) age was 61.7 ± 14.2 years with 57.7% of the patients being male and 42.3% being female. The mean IDWG% for the whole studied population was 3.72% ± 1.73%. Between these three groups, a higher IDWG% was associated with younger males (p = 0.032), lower dry weight (p = 0.009), and longer duration on HD therapy (p = 0.009). IDWG% was directly associated with lower pre-dialysis serum sodium (p = 0.04), higher pre-dialysis serum creatinine (P = 0.002), and lower body mass index (BMI) (p= 0.003). Between these three groups, interdialytic variations in weight gain were not associated with increased BP. There was no significant difference between the three groups in terms of nPNA and serum albumin. Conclusions The most important associations of IDWG% are age, weight, pre-dialysis sodium, serum creatinine, and duration of dialysis (months). There was no association between IDWG% and increased systolic BP. IDWG% had no association with nutritional status.
Collapse
Affiliation(s)
- Mojgan Jalalzadeh
- Internal Medicine/Nephrology, Metropolitan Hospital Center, New York Medical College, New York, USA
| | | | - Camila Villavicencio
- Internal Medicine, Metropolitan Hospital Center, New York Medical College, New York, USA
| | - Muhammad Aameish
- Internal Medicine/Nephrology, Metropolitan Hospital Center, New York Medical College, New York, USA
| | - Shobhana Chaudhari
- Internal Medicine/Geriatrics, Metropolitan Hospital Center, New York Medical College, New York, USA
| | - Donald Baumstein
- Internal Medicine/Nephrology, Metropolitan Hospital Center, New York Medical College, New York, USA
| |
Collapse
|
2
|
Jalalzadeh M, Garcia Goncalves de Brito D, Chaudhari S, Poor AD, Baumstein D. Gitelman Syndrome Provisionally Diagnosed During the First Presentation of Diabetic Ketoacidosis. Cureus 2021; 13:e14253. [PMID: 33954067 PMCID: PMC8088595 DOI: 10.7759/cureus.14253] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Gitelman syndrome (GS) is an autosomal recessive disease characterized by hypokalemia, hypomagnesemia, metabolic alkalosis, and hypocalciuria. It is caused by mutations in gene SLC12A3 (located in chromosome 16q) encoding NaCl cotransporter. GS is usually asymptomatic for several years and is diagnosed in late childhood or adulthood. The association between GS and diabetic ketoacidosis (DKA) is rare. We present a case of a 25-year-old man with newly diagnosed diabetes mellitus and DKA with profound hypokalemia and hypomagnesemia who was provisionally found to have GS.
Collapse
Affiliation(s)
- Mojgan Jalalzadeh
- Internal Medicine/Nephrology, Metropolitan Hospital Center, New York Medical College, New York, USA
| | | | - Shobhana Chaudhari
- Internal Medicine/Geriatrics, Metropolitan Hospital Center, New York Medical College, New York, USA
| | - Armeen D Poor
- Internal Medicine/Pulmonary Critical Care, Metropolitan Hospital Center, New York Medical College, New York, USA
| | - Donald Baumstein
- Internal Medicine/Nephrology, Metropolitan Hospital Center, New York Medical College, New York, USA
| |
Collapse
|
3
|
Jalalzadeh M, Chaudhari A, Baumstein D. Prolonged Altered Mental Status in a Diabetic Hemodialysis Patient. Cureus 2021; 13:e13132. [PMID: 33728148 PMCID: PMC7936650 DOI: 10.7759/cureus.13132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Osmotic demyelination syndrome (ODS) is a demyelinating disorder of the central nervous system. It usually occurs with rapid correction of severe chronic hyponatremia. ODS is rarely seen as a complication of hyperglycemia. Herein, we report a rare presentation of ODS secondary to hyperosmolar hyperglycemic state. A 28-year-old female with type 1 diabetes, hypertension, seizure disorder, and end-stage renal disease on hemodialysis was brought from a shelter with two days of unresponsiveness and developed ODS after hyperosmolar hyperglycemic state in long-standing uncontrolled diabetes with normal serum electrolyte levels.
Collapse
Affiliation(s)
- Mojgan Jalalzadeh
- Internal Medicine/Nephrology, Metropolitan Hospital Center, New York Medical College, New York, USA
| | - Ashok Chaudhari
- Internal Medicine/Nephrology, Metropolitan Hospital Center, New York Medical College, New York, USA
| | - Donald Baumstein
- Internal Medicine/Nephrology, Metropolitan Hospital Center, New York Medical College, New York, USA
| |
Collapse
|
4
|
Jalalzadeh M, Valencia-Manrique JC, Boma N, Chaudhari A, Chaudhari S. Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis in a Case of Scleroderma After Recent Diagnosis With COVID-19. Cureus 2021; 13:e12485. [PMID: 33564500 PMCID: PMC7861062 DOI: 10.7759/cureus.12485] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare occurrence in systemic sclerosis (SSc) patients. AAV is an inflammatory disease that can lead to kidney failure due to the infiltration of mononuclear cells and the destruction of blood vessels. Also, crescentic glomerulonephritis (GN) has rarely been reported with coronavirus disease 2019 (COVID-19) and acute tubular injury is the most common renal pathology lesion in these patients. We present a rare case of a 46-year-old woman with SSc with new onset of renal failure after a recent diagnosis of COVID-19. Her serology was positive for p-ANCA and myeloperoxidase antibodies. Kidney biopsy was done and showed crescentic GN. We suggest during this pandemic, patients with an immunological disorder that are infected with COVID-19 be closely monitored for any organ involvement.
Collapse
Affiliation(s)
- Mojgan Jalalzadeh
- Internal Medicine/Nephrology, Metropolitan Hospital Center, New York Medical College, New York, USA
| | | | - Noella Boma
- Internal Medicine, Metropolitan Hospital Center, New York Medical College, New York, USA
| | - Ashok Chaudhari
- Internal Medicine/Nephrology, Metropolitan Hospital Center, New York Medical College, New York, USA
| | - Shobhana Chaudhari
- Internal Medicine/Geriatrics, Metropolitan Hospital Center, New York Medical College, New York, USA
| |
Collapse
|
5
|
Jalalzadeh M, Mousavinasab SN, Rostami A. Relationship of circulating levels of 25(OH)D with parathyroid hormone in various stages of chronic kidney disease. J Renal Inj Prev 2017. [DOI: 10.15171/jrip.2017.50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
6
|
Jalalzadeh M, Ghadiani MH. Kidney Failure Due to Abdominal Compartment Syndrome Following Snakebite. Iran J Kidney Dis 2017; 11:66-69. [PMID: 28174355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 03/22/2016] [Revised: 08/17/2016] [Accepted: 09/04/2016] [Indexed: 06/06/2023]
Abstract
Treatment of snakebite complications is challenging, as it is difficult to distinguish what kind of antivenins should be used. Kidney failure as a result of rhabdomyolysis or hemolysis may happen due to accumulated fluids that increase the pressure in the abdomen. This case report describes acute kidney failure probably due to intra-abdominal hypertension following an unknown bite.
Collapse
Affiliation(s)
- Mojgan Jalalzadeh
- Department of Nephrology, Loghman-Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
| | | |
Collapse
|
7
|
Jalalzadeh M, Mousavinasab N, Soloki M, Miri R, Ghadiani MH, Hadizadeh M. Association between metabolic syndrome and coronary heart disease in patients on hemodialysis. Nephrourol Mon 2015; 7:e25560. [PMID: 25738129 PMCID: PMC4330693 DOI: 10.5812/numonthly.25560] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2014] [Revised: 12/18/2014] [Accepted: 01/13/2015] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND The metabolic syndrome (MeS) is a common risk factor for coronary heart disease (CHD) in the general population. OBJECTIVES We examined the association between MeS and its risk in terms of CHD in patients on hemodialysis (HD). PATIENTS AND METHODS This study was conducted on 300 patients on HD in six HD centers during March 2012. Patients were divided in two groups regarding presence of MeS. The rate of CHD were evaluated in each group and compared with each other. RESULTS A total of 300 patients on HD, 173 males and 127 females with mean age of 61.7 ± 14.2, were enrolled in the study. Prevalence of MeS was 50.3%; hypertension, 83.7%; diabetes mellitus, 52%; high triglyceride level, 34%, low HDL cholesterol, 48.3%; and abdominal obesity, 41.3%. During the study, the CHD was more frequent in patients with MeS (27.8%) than was in those without MeS (14.1%) (P = 0.004). In addition, stroke happened more frequently in the MeS group than in those without MeS (30.5% vs. 17.4%; P = 0.008). The mean number of criteria for MeS was not significantly associated with mortality causes (CHD, 2.7 ± 1.3; stroke, 2.8 ± 0.9; other causes, 2.9 ± 1.3 P = 0.78). However, hypertension (89.3%) and diabetes mellitus (53.8%) were associated with increased risk for mortality. In the group of MeS, CHD were not significantly associated with serum albumin, calcium, phosphate, blood urea nitrogen, creatinine, ferritin, C-reactive protein, and KT/V; but there was significant association with white blood cells count (P < 0.0002). CONCLUSIONS These findings suggested MeS might be an important risk factor for CHD, but not for mortality due to CHD in patients on HD.
Collapse
Affiliation(s)
- Mojgan Jalalzadeh
- Department of Nephrology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
| | | | - Mehrdad Soloki
- Department of Pulmonary, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
| | - Reza Miri
- Department of Cardiology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
| | - Mohammad Hassan Ghadiani
- Department of Nephrology, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
- Corresponding author: Mohammad Hassan Ghadiani, Department of Nephrology, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran. Tel: +98-2173430001, E-mail:
| | - Maryam Hadizadeh
- Vice Chancellor, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
| |
Collapse
|
8
|
Jalalzadeh M, Mousavinasab N, Peyrovi S, Ghadiani MH. The impact of acute rejection in kidney transplantation on long-term allograft and patient outcome. Nephrourol Mon 2015; 7:e24439. [PMID: 25738128 PMCID: PMC4330708 DOI: 10.5812/numonthly.24439] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2014] [Revised: 11/01/2014] [Accepted: 11/05/2014] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Patients with end stage renal disease (ESRD) can be sustained with dialysis therapy. OBJECTIVES In this study, we followed up the effect of early acute and late acute rejections on survival rates of patients' grafts. PATIENTS AND METHODS We investigated the timing and frequency of acute rejection episodes related to long-term patient-graft survival in Taleghani hospital between 1990 and 2011. Recipients were divided into three groups as Group-1 (no rejection), Group-2 (early acute rejection [EAR]: less than 3-months) and Group-3 (late acute rejection [LAR]: after 3 months of transplant). RESULTS One and five-year patient's survival rates were 94.87% and 93.8%, and graft survival (GS) rates were 92.6% and 81.9%. EAR and LAR occurred in 125 (18.8%) and 77 (11.7%) patients, respectively. Graft and patient survival rates at one and five years were as follows; Group-1 (Graft 96.7% and 94.5% patient: 97.4% and 96.8%), Group-2 (Graft: 72% and 61%, patient: 85.6% and 84%), Group-3 (Graft: 84.4% and 36.8%, patient: 92.2% and 89.4%). Recipient age, type and length of dialysis, number of transplantations and the status of panel reactivity antibody (PRA) had no effect on the type of rejection. LAR was more commonly associated with males (P = 0.001) and donors' age was associated with rejection (P = 0.0002). Five-year GS rate among the three groups was lower in the LAR group (P < 0.0001). CONCLUSIONS LAR had a negative impact on long-term renal allograft survival and the risk of chronic graft dysfunction increased in patients with a history of LAR.
Collapse
Affiliation(s)
- Mojgan Jalalzadeh
- Department of Nephrology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
| | | | - Said Peyrovi
- Maraghe University of Medical Sciences, Maraghe, IR Iran
| | - Mohammad Hassan Ghadiani
- Department of Nephrology, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
| |
Collapse
|
9
|
Vafaeimanesh J, Jalalzadeh M, Nazarian M. Expression comparison of azithromycin and clarithromycin in triple-therapy regimens for eradication of Helicobacter pylori in hemodialysis patients. Saudi J Kidney Dis Transpl 2014; 25:53-7. [PMID: 24434382 DOI: 10.4103/1319-2442.124486] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
To compare a triple-therapy regimen based on change of antibiotic (azithromycin and clarithromycin) for the eradication of Helicobacter pylori in hemodialysis (HD) patients, we studied in a prospective, randomized, double-blinded clinical trial 39 patients who had dyspepsia and showed two positive results from the diagnostic tests of H. pylori infection including anti-H. pylori serology and stool antigen (HpSAg) and urease breath test (UBT). The patients were divided into two groups: Group-A received omeprazol 20 mg, amoxycilin 500 mg and clarithromycin 500 mg twice a day and Group-B received omeprazol 20 mg, amoxicillin 500 mg and azithromycin 250 mg twice a day. The adverse events and compliance with triple therapy were reviewed at one visit per week. Both groups were prescribed their medications for 14 days. Of the 39 patients, only 37 patients completed the treatment schedule (20 men and 19 women, with the mean being 59 years). Two patients died due to myocardial infarction before the start of treatment and were out of the study. The eradication rate of H. pylori, evaluated by negative results of UBT, was 82.4% in Group-A and 80% in Group-B (P-value = 1.0). The results of our study showed no significant difference of azitromycin versus claritromycin in the eradication of H. pylori infection in HD patients.
Collapse
Affiliation(s)
- Jamshid Vafaeimanesh
- Clinical Research Development Center, Qom University of Medical Sciences, Qom, Iran
| | | | | |
Collapse
|
10
|
Rostami Z, Einollahi B, Lessan-Pezeshki M, Soleimani Najaf Abadi A, Mohammadi Kebar S, Shahbazian H, Makhlough A, Makhdoomi K, Salesi M, Jalalzadeh M. Health-related quality of life in hemodialysis patients: an Iranian multi-center study. Nephrourol Mon 2013; 5:901-12. [PMID: 24350090 PMCID: PMC3842562 DOI: 10.5812/numonthly.12485] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2013] [Accepted: 05/28/2013] [Indexed: 01/09/2023] Open
Abstract
Background The effectiveness of health care and health policy developments are often determined by health-related quality of life (HRQOL) assessment. Objectives The objective of this study was to explore the potential corresponding factors and traditional biomarkers of HRQOL in a large number of Iranian hemodialysis patients. Patients and Methods A total of 6,930 chronic hemodialysis (HD) patients enrolled. KDCS-SF version 1.3 questionnaire was used to assess the health related quality of life (HRQOL). We pooled PCS, MCS and KDCS scores with random effect model from 19 similar studies performed between 1996 and 2010 Results The mean age was 54.4 ± 17.1 years. Mean PCS, MCS and KDCS scores obtained for the study cohort were 40.79 ± 20.10, 47.79 ± 18.31 and 57.97 ± 11.70, respectively; the total score of SF-36 plus KDCS was 51.12 ± 13.41 as well. The most common primary known disease was hypertension (31.9%) and the second etiology was diabetes (25.5%). In multilevel logistic regression, Kt/V between 1 and 1.2 and PCS, KDCS more than 50 were considered as a significant reduction in the risk of hospitalization. Conclusions This study showed that PCS and MCS score were slightly more than overall results while KDCS was slightly less than overall results. In addition, dialysis adequacy with Kt/V between 1 and 1.2 is associated with lower rate of hospitalization.
Collapse
Affiliation(s)
- Zohreh Rostami
- Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
- Corresponding author: Zohreh Rostami, Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran. Tel: +98-9121544897, Fax: +98-2188934125, E-mail:
| | - Behzad Einollahi
- Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
| | | | | | | | | | - Atieh Makhlough
- Department of Nephrology, Sari University of Medical Sciences, Sari, IR Iran
| | - Khadijeh Makhdoomi
- Department of Nephrology, Urmia University of Medical Sciences, Urmia, IR Iran
| | - Mahmood Salesi
- Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
| | - Mojgan Jalalzadeh
- Department of Nephrology, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
| |
Collapse
|
11
|
Jalalzadeh M, Nurcheshmeh Z, Mohammadi R, Mousavinasab N, Ghadiani MH. The effect of allopurinol on lowering blood pressure in hemodialysis patients with hyperuricemia. J Res Med Sci 2012; 17:1039-46. [PMID: 23833578 PMCID: PMC3702085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/07/2012] [Revised: 07/17/2012] [Accepted: 08/18/2012] [Indexed: 11/13/2022]
Abstract
BACKGROUND Hyperuricemia has been associated with the development of high blood pressure (BP). We studied the effects of allopurinol therapy in hyperuricemic hemodialysis (HD) patients with high BP. MATERIALS AND METHODS This single-blind, randomized cross-over clinical study involved 55 HD patients with serum uric acid level > 6.5 (men) and > 5.5 mg/dL (women). They were randomly divided in two groups, each of which went through two phases. Group-1 in phase-1 received 100 mg/day orally of allopurinol for three months; while Group-2 was given whatever medication they received prior to the study. After two months of washing period, the groups were crossed-over. The BP levels were measured before and after HD during the eight months study period. RESULTS Fifty-three patients completed the study (33 men and 20 women, with mean age of 55.8 years). Uric acid levels decreased significantly during the12 weeks of allopurinol therapy (7.71 ± 1.53 to 5.2 ± 1.2 P < 0.005). Overall, after the 12 weeks of allopurinol therapy, systolic and diastolic BP also significantly decreased in allopurinol group, 15.8% (139 to 117, P < 0.0005) and 8.6% (81 to 74, P <.0005), respectively. There were not significant changes in body mass index, blood urea nitrogen, creatinine, albumin, cholesterol, triglyceride, hemoglobin, liver enzymes and serum electrolytes level after treatment. Patients treated with allopurinol had a significant increase in the quality of dialysis (KT/V) (P: 0.043). CONCLUSIONS In HD patients, allopurinol treatment reduced BP. The results indicate a new potential therapeutic approach for controlling BP in HD patients.
Collapse
Affiliation(s)
- Mojgan Jalalzadeh
- Department of Nephrology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Iran
| | | | - Ramin Mohammadi
- Department of Nephrology, Vali-e-Asr hospital, Zanjan University of Medical Sciences, Iran
| | | | - Mohammad Hassan Ghadiani
- Department of Nephrology, Taleghani hospital, Shahid Beheshti University of Medical Sciences, Iran,Address for correspondence: Dr. Mohammad Hassan Ghadiani, Taleghani Hospital of Shahid Beheshti, University of Medical Sciences, Tehran, Iran. E-mail:
| |
Collapse
|
12
|
Jalalzadeh M, Shekari E, Mirzamohammadi F, Ghadiani MH. Effect of short-term intravenous ascorbic acid on reducing ferritin in hemodialysis patients. Indian J Nephrol 2012; 22:168-73. [PMID: 23087549 PMCID: PMC3459518 DOI: 10.4103/0971-4065.86407] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Resistance to recombinant erythropoietin (rEPO) in hemodialysis patients may be due to inadequate iron recruitment and defect in iron use. In this cross over randomized clinical trial, 30 hemodialysis patients with serum ferritin levels of ≥500 ng/ml, hemoglobin ≤11.0 g/dl, and transferrin saturation (TSAT) of 20% or less were administrated intravenous iron (50-100 mg/wk) and rEPO (120-360 U/kg/wk) for 6 months. Patients were excluded if there was a clear explanation for rEPO hyporesponsiveness. Patients were divided into two groups. Group1 received standard care and 500 mg of intravenous ascorbic acid (IVAA) with each dialysis session in the first week of each month for a total of 3 months. Group 2 received standard care only. After 2 month washout period, groups were crossed over. Each month hemoglobin (Hb) was assessed. Iron, TIBC (transferrin iron binding capacity), TSAT, iPTH (intact parathyroid hormone), liver enzymes, albumin and cholesterol levels were measured every 3 months. After 3 months of intervention, Hb significantly increased from 10.11 to 12.19 g/dl (P <0 0.001; 95% confidence interval [CI] 2.7-1.4) and TSAT increased from 18.9 to 28.1% (P = 0.008; 95% CI 0.09-3), while ferritin and serum iron declined significantly from 1391 to 938 ng/ml (P = 0.001; 95% CI 216-689), 97.2 to 64.6 (P = 0.001; 95% CI 14.8-50.4) in the study group. Change of Hb over time in IVAA group was significant (P < 0.0005). There were significant differences between two groups in change of Hb level over time (P < 0.0005) and treatment effect (P = 0.002). Baseline laboratory tests were similar in the two groups and there was no carry over effect at phase 2. We showed that low amount of IVAA could reduce ferritin level and enhance Hb and TSAT, suggesting improved iron utilization.
Collapse
Affiliation(s)
- M Jalalzadeh
- Department of Nephrology, Imam Hossein Hospital, Tehran, Iran
| | | | | | | |
Collapse
|
13
|
Jalalzadeh M, Ghadiani MH, Mousavinasab N. Association between helicobacter pylori infection and body mass index, before and after eradication of infection in hemodialysis batients. J Nephropathol 2012; 1:170-6. [PMID: 24475411 DOI: 10.5812/nephropathol.8115] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2012] [Revised: 05/30/2012] [Accepted: 06/02/2012] [Indexed: 01/29/2023] Open
Abstract
BACKGROUND In dialysis patients, chronic infections have been associated with cachexia and anorexia. OBJECTIVES This study was carried out to determine the association between Helicobacter pylori (HP) infection and body mass index (BMI) in hemodialysis (HD) patients. PATIENTS AND METHODS Ninety eight patients were divided into two groups of negative (group 1) and positive (group 2), for HP. BMI of all patients was measured at the beginning and in group2 after six months following eradication of HP. Before dialysis, various paraclinical parameters were checked at the same intervals. RESULTS Fifty-nine patients were enrolled in group 1 and 39 patients in group 2. The means of BMI in groups 1 and 2 were 23.4±3.7 and 25.8±4.4kg/m², respectively. Prior to the study, there was no significant difference for BMI, duration of HD and paraclinic data between two groups. Group 2 took anti HP therapy and eradication occurred in 30 of them. In this group six months after eradication of HP, the BMI was significantly decreased from 25.02±4.4 to 24.4±4.0 kg/m² (P = 0.001). Also six months following the eradication of HP, the mean of serum albumin level was significantly declined from 4.2 to 3.7 g/L (P<0.001). There was also significant decrease in cholesterol (P=0.001), blood urea nitrogen (P=0.005) and calcium (P=0.02). However, significant increase in hemoglobin level was also seen (P=0.03). CONCLUSIONS The results of this study show that eradication of HP has an impact on BMI. The results need to be investigated with larger cases.
Collapse
Affiliation(s)
- Mojgan Jalalzadeh
- Departments of Nephrology , Imam Hossein Hospital , Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Mohammad Hassan Ghadiani
- Department of Nephrology. Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | | |
Collapse
|
14
|
Jalalzadeh M, Nazarian M, Vafaeimanesh J, Mirzamohammadi F. Comparison of azithromycin and clarithromycin triple therapy regimens for helicobacter pylori eradication in hemodialysis patients. Nephrourol Mon 2012; 4:571-7. [PMID: 23573488 PMCID: PMC3614284 DOI: 10.5812/numonthly.2794] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2011] [Revised: 11/17/2011] [Accepted: 11/27/2011] [Indexed: 02/06/2023] Open
Abstract
Background Helicobacter pylori eradication with clarithromycin is more expensive than with azithromycin. Objectives This study aimed to compare the effectiveness of these two antibiotics in eradicating H. pylori in hemodialysis (HD) patients. Patients and Methods This is a prospective, randomized, double-blinded clinical trial analysis of HD patients. Patients who had dyspepsia and showed positive results for two of three tests, anti-H. pylori serology, H. pylori stool antigen (HpSAg), or Urease Breath Test (UBT), were included in the study. The subjects consisted of 39 dialysis patients who were randomly divided into two groups that received medication twice daily. Group OAC received 20 mg omeprazol, 500 mg amoxycilin, and 250 mg clarithromycin, and Group OAAz received 20 mg omeprazol, 500 mg amoxicillin, and 250 mg azithromycin. Both regimens were administered for 14 days. Eradication was investigated by performing the UBT and the HpSAg test eight weeks later. Results This study began with 39 patients, 37 of which completed the treatment schedule (20 males and 17 females, mean age 59 years). Two patients died due to MI before beginning treatment. In the OAC group, negative results on the UBT and HpSAg tests were found in 82.4% and 88.2% of the participants, respectively. In the OAAz group, these values were 80% and 85%, respectively. The data showed that the difference between the two regimens was not significant (P = 1.0). Conclusions According to the data, no differences in eradication rates were apparent between the azitromycin and the claritromycin regimens. However, lower cost and fewer complaints could be considered as an advantage of the triple therapy with azithromycin.
Collapse
Affiliation(s)
- Mojgan Jalalzadeh
- Departments of Nephrology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
| | - Morteza Nazarian
- Departments of Gastroetrology, Vali-e-asr Hospital, Zanjan University of Medical Sciences, Zanjan, IR Iran
| | - Jamshid Vafaeimanesh
- Departments of Internal Medicine, Qom University of Medical Sciences, Qom, IR Iran
- Corresponding author: Jamshid Vafaeimanesh, Departments of Internal Medicine, Qom University of Medical Sciences, Qom, IR Iran. Tel.: +989122248306, Fax: +9824122782476, E-mail:
| | - Fatemeh Mirzamohammadi
- Student Research Committee, Vali-e-asr Hospital, Zanjan University of Medical Sciences, Zanjan, IR Iran
| |
Collapse
|
15
|
Einollahi B, Rostami Z, Nourbala MH, Lessan-Pezeshki M, Simforoosh N, Nemati E, Pourfarziani V, Beiraghdar F, Nafar M, Pour-Reza-Gholi F, Mazdeh MM, Amini M, Ahmadpour P, Makhdoomi K, Ghafari A, Ardalan MR, Khosroshahi HT, Oliaei F, Shahidi S, Abbaszadeh S, Fatahi MR, Hiedari F, Makhlogh A, Azmandian J, Samimagham HR, Shahbazian H, Nazemian F, Naghibi M, Khosravi M, Monfared A, Mosavi SM, Ahmadi J, Jalalzadeh M. Incidence of malignancy after living kidney transplantation: a multicenter study from iran. J Cancer 2012; 3:246-56. [PMID: 22712025 PMCID: PMC3376775 DOI: 10.7150/jca.3042] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2011] [Accepted: 08/09/2011] [Indexed: 12/17/2022] Open
Abstract
Malignancy is a common complication after renal transplantation. However, limited data are available on post-transplant malignancy in living kidney transplantation. Therefore, we made a plan to evaluate the incidence and types of malignancies, association with the main risk factors and patient survival in a large population of living kidney transplantation. We conducted a large retrospective multicenter study on 12525 renal recipients, accounting for up to 59% of all kidney transplantation in Iran during 22 years follow up period. All information was collected from observation of individual notes or computerized records for transplant patients. Two hundred and sixty-six biopsy-proven malignancies were collected from 16 Transplant Centers in Iran; 26 different type of malignancy categorized in 5 groups were detected. The mean age of patients was 46.2±12.9 years, mean age at tumor diagnosis was 50.8±13.2 years and average time between transplantation and detection of malignancy was 50.0±48.4 months. Overall tumor incidence in recipients was 2%. Kaposis' sarcoma was the most common type of tumor. The overall mean survival time was 117.1 months (95% CI: 104.9-129.3). In multivariate analysis, the only independent risk factor associated with mortality was type of malignancy. This study revealed the lowest malignancy incidence in living unrelated kidney transplantation.
Collapse
Affiliation(s)
- Behzad Einollahi
- 1. Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Ghadiani MH, Besharati S, Mousavinasab N, Jalalzadeh M. Response rates to HB vaccine in CKD stages 3-4 and hemodialysis patients. J Res Med Sci 2012; 17:527-33. [PMID: 23626628 PMCID: PMC3634289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/19/2012] [Revised: 06/12/2012] [Accepted: 06/14/2012] [Indexed: 11/25/2022]
Abstract
BACKGROUND Hepatitis-B virus (HBV) infection is a big problem in chronic kidney disease (CKD) population. We attempted to compare the response rate to HB vaccine in CKD stages3-4 patients with that in hemodialysis (CKD stage-5; HD patients) and medical staff. MATERIALS AND METHODS Three hundred and three participants were enrolled into the study to test the seroconversion rate after vaccination. Participants formed three groups: Group-A:HD patients, Group-B: diagnosed with CKD stages 3-4, and Group-C: healthy medical staff. CKD stages 3-4 participants were vaccinated from February to November 2010. HD patients were vaccinated at the time of initial HD. While the medical staffs were vaccinated at the time they started working at the hospital. Group-A, Group-B and Group-C received four 40μg (in 0,1,2 and 6 months), three 40μg (0, 1 and 6 months) and three 20μg (0, 1and 6 months) doses of HB vaccine, respectively. Three months after completion of the vaccination schedule, seroconversion and seroprotection rates in each group were investigated. RESULTS Seroconversion rates were 44.3%, 89.7%, and 96.2% for groups A, B and C, respectively. CKD stages 3-4 patients showed higher response rate than dialysis patients [χ(2)(1):30.6, P <0.001]. But a significant difference in the seroconversion rate between CKD stages 3-4 patients and medical staffs was not observed [χ(2)(1):3.4, P = 0.064]. Multivariate analyses showed patients with more advanced CKD and who were older had less seroconversion rates [odds ratio: 0.09(95%CI: 0.04 - 0.25) and [odds ratio: 0.39(95% CI: 0.18-0.85)], respectively. But sex was not associated with seroconversion (P>0.05). CONCLUSION Stages 3-4 patients with higher dosages of routine HB vaccine had higher seroconversion rate than HD patients. Future studies should evaluate the recommended dosage of HB vaccine among these patients.
Collapse
Affiliation(s)
- Mohammad H. Ghadiani
- Department of Nephrology, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Shahin Besharati
- Department of Internal Medicine,Vali-e-asr Hospital, Zanjan University of Medical Sciences, Zanjan, Iran
| | - Nouraddin Mousavinasab
- Department of Social Medicine, School Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
| | - Mojgan Jalalzadeh
- Department of Nephrology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran,Address for correspondence: Dr. Mojgan Jalalzadeh, Assistant Professor, Department of Nephrology and Dialysis, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. E-mail:
| |
Collapse
|
17
|
Ghadiani MH, Peyrovi S, Mousavinasab SN, Jalalzadeh M. Delayed graft function, allograft and patient srvival in kidney transplantation. Arab J Nephrol Transplant 2012; 5:19-24. [PMID: 22283862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
INTRODUCTION Delayed Graft Function (DGF) is a common complication of renal transplants and the long-term relation between DGF and survival of patients and grafts is not well established. METHODS This is a historical cohort study of transplanted patients in Taleghani Hospital of Shahid Beheshti University in Iran between 1994 and 2010. Patients who required dialysis during the first week after transplantation were considered to have DGF. The patients' conditions were updated to determine existing graft function, graft loss or patients' death at one year and five years post transplantation in relation to the presence or absence of DGF. RESULTS DGF complicated 67/385 transplants (17.4%). Causes included acute tubular necrosis (58.2%), accelerated rejection (29.9%), transplant renal artery thrombosis (9%) and renal vein thrombosis (3%). More kidneys in the DGF group were procured from cadaveric donors (6% versus 0.9%, P = 0.02). At hospital discharge, patients with DGF had significantly higher mean creatinine level (4.4 ± 2.8 versus 2.0 ± 1.7; P = 0.001) compared to other patients. They also had more early acute rejection episodes and more late acute rejection episodes (34.3% versus 2% and 16.4% versus 3%, respectively; P = 0.0001) compared to other patients. The proportion of functioning grafts was significantly lower in the DGF group at 1-year (53.7% versus 95.3%, P = 0.0001) and 5-years (22.4% versus 61.6%, P = 0.001) compared to patients without DGF. CONCLUSION The DGF group had a significantly higher acute rejection rate and an increased risk of graft loss at one and five years.
Collapse
|
18
|
Jalalzadeh M, Mohammadi R, Mirzamohammadi F, Ghadiani MH. Prevalence of metabolic syndrome in a hemodialysis population. IRANIAN JOURNAL OF KIDNEY DISEASES 2011; 5:248-254. [PMID: 21725182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 08/10/2010] [Accepted: 03/06/2011] [Indexed: 05/31/2023]
Abstract
INTRODUCTION The role of metabolic syndrome (MS) in hemodialysis population has not been thoroughly studied. This study aimed to determine the prevalence of MS and to identify its correlates among hemodialysis patients. MATERIALS AND METHODS This cross-sectional study was conducted on patients in a hemodialysis center. The MS was defined according the Adult Treatment Panel III criteria. Clinical data of the patients were collected and blood samples were studied to measure fasting blood glucose and lipid profile. RESULTS Eighty hemodialysis patients, including 47 men (58.8%) and 33 women (41.2%) with a mean age of 55.6 ± 15.6 years, were enrolled in this study. Metabolic syndrome was diagnosed in 23 patients (28.7%). Hypertension was present in 55 patients (68.8%). Fifteen patients (18.8%) were diabetic, 24 (30.0%) had a high serum triglyceride, 22 (27.5%) had a low high-density lipoprotein cholesterol, and 20 (25.0%) had evidence of abdominal obesity. Patients with MS had significantly higher body mass indexes (P < .001), fasting blood glucose levels (P < .001), and triglyceride levels (P = .004). Metabolic syndrome was not associated with gender, age, and duration of hemodialysis. Men showed significant abnormality in glucose metabolism (P = .008). Prevalence of low high-density lipoprotein cholesterol was significantly higher in the women than in the men (P = .02). CONCLUSIONS The prevalence of MS in our hemodialysis patients was relatively high, with the most common element being hypertension. We suggest that there needs to be a new set of criteria defined for MS in hemodialysis patients.
Collapse
Affiliation(s)
- Mojgan Jalalzadeh
- Department of Nephrology, Zanjan University of Medical Sciences, Zanjan, Iran
| | | | | | | |
Collapse
|
19
|
Falaknazi K, Jalalzadeh M, Vafaeimanesh J. Noninvasive stool antigen assay for screening of Helicobacter pylori infection and assessing success of eradication therapy in patients on hemodialysis. Iran J Kidney Dis 2010; 4:317-321. [PMID: 20852374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 12/13/2009] [Accepted: 10/14/2010] [Indexed: 05/29/2023]
Abstract
INTRODUCTION. Helicobacter pylori infection can be diagnosed by biopsy-based or noninvasive methods. Our aim was to identify H pylori-positive patients on hemodialysis by the noninvasive method of H pylori stool antigen (HPSA) and investigate its diagnostic accuracy for assessment of the eradication of infection after treatment in comparison with urea breath test (UBT). MATERIALS AND METHODS. Serology, HPSA, and UBT were performed on 87 hemodialysis patients. Infection with H pylori was confirmed if at least 2 tests were positive. Patients with H pylori infection received a 2-week course of triple therapy. To evaluate success of eradication HPSA and UBT were done after 8 weeks. RESULTS. Eighty-seven patients were enrolled in the study, of whom 39 (44.8%) were proved to have H pylori infection. The HPSA was positive in the stool specimens of 37 patients (42.5%) and the serology test was positive in 39 (44.8%). The HPSA had a 87.1% sensitivity and a 93.7% specificity for detection of H pylori infection. Thirty-seven patients completed the treatment period. Success of H pylori eradication was documented in 30 of the 37 patients (81.1%) based on UBT. After the treatment, the HPSA was negative in 32 of 37 of the stool specimens (86.4%), showing a 42.8% sensitivity and a 93.3% specificity to detect the failure of eradication of H pylori. CONCLUSIONS. Helicobacter pylori stool antigen assay is a noninvasive reliable tool to screen H pylori infection before therapy and assess the success of eradication in patients on hemodialysis.
Collapse
Affiliation(s)
- Kianoosh Falaknazi
- Department of Nephrology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | | | | |
Collapse
|
20
|
Jalalzadeh M, Saber HR, Vafaeimanesh J, Mirzamohammadi F, Falaknazi K. Association of Helicobacter pylori infection and serum albumin in patients on hemodialysis. Iran J Kidney Dis 2010; 4:312-316. [PMID: 20852373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 12/11/2009] [Revised: 05/18/2010] [Accepted: 07/19/2010] [Indexed: 05/29/2023]
Abstract
INTRODUCTION. Helicobacter pylori infection in gastric mucosa may cause systemic inflammatory reaction. We investigated the inflammatory effect of H pylori infection on nutritional factors such as serum albumin in hemodialysis patients and influence of eradication of H pylori on this association. MATERIALS AND METHODS. Ninety-eight patients on hemodialysis were divided into 2 groups according to H pylori infection. Eradication of H pylori, 8 weeks after treatment, was confirmed by urease breath test and H pylori stool antigen. Serum albumin, lipid profile, and metabolite levels were checked before and after 8 weeks and 6 months of eradication of H pylori. RESULTS. Thirty-nine patients (39.8%) were infected with H pylori. There were no significant differences between the two groups in age, dialysis duration, serum albumin, serum creatinine, blood urea nitrogen, hemoglobin, serum calcium, serum phosphorus, and lipid profile. Thirty-seven patients with H pylori completed the treatment period. Eradication was successful in 30 patients (81.1%). Eight weeks and 6 months after anti-H pylori drug therapy, the mean serum albumin level significantly decreased from 4.2 mg/dL to 3.6 mg/dL (P < .001) and 3.7 mg/dL (P < .001), respectively. Significant decreases were seen in serum cholesterol (P = .001), blood urea nitrogen (P = .005), and serum calcium level (P = .03) and a significant increase in hemoglobin level (P = .02). CONCLUSIONS. Our study did not demonstrate nutritional benefits after H pylori eradication treatment, as the level of nutritional markers reduced. This relationship needs to be confirmed by further prospective studies.
Collapse
Affiliation(s)
- Mojgan Jalalzadeh
- Department of Nephrology, Zanjan University of Medical Sciences, Iran.
| | | | | | | | | |
Collapse
|
21
|
Einollahi B, Jalalzadeh M, Taheri S, Nafar M, Simforoosh N. Outcome of kidney transplantation in type 1 and type 2 diabetic patients and recipients with posttransplant diabetes mellitus. Urol J 2008; 5:248-254. [PMID: 19101899] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
INTRODUCTION We aimed to assess the effects of different types of diabetes mellitus (DM) on patients receiving living donor kidney allografts. MATERIALS AND METHODS A total of 111 kidney transplant patients with DM and 111 randomly selected kidney transplant recipients without DM were enrolled in the study. The characteristics of the kidney allograft recipients and the allograft and patient outcomes were assessed and compared between 4 groups of kidney recipients without DM and patients with type 1 DM, type 2 DM, and posttransplant DM. RESULTS Of the 111 patients with DM, 36 (32.4%), 20 (18.0%), and 55 (49.6%) had been diagnosed with type 1 DM, type 2 DM, and posttransplant DM, respectively. Diabetic patients had significantly higher rates of rejection episodes (P = .049) and suffered more frequently from delayed graft function (P = .03) compared to the kidney recipients in the control group. Patient and allograft survival rates were significantly lower in the patients with DM (regardless of their DM type) compared to the nondiabetic patients (P = .03 and P = .04, respectively). Prominently, type 1 DM had significantly adverse effects on patient and allograft survival. Patients with posttransplant DM had a relatively better patient survival compared to those with type 1 DM and type 2 DM. CONCLUSION We found that kidney recipients with DM, especially preexisting DM, had worse patient and graft survival rates compared to the nondiabetics. These findings suggest that kidney transplant patients presenting with any type of DM should be more closely followed.
Collapse
Affiliation(s)
- Behzad Einollahi
- Nephrology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
| | | | | | | | | |
Collapse
|